B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

DHFR

MOLECULAR TARGET

dihydrofolate reductase

UniProt: P00374NCBI Gene: 171917 compounds

DHFR (dihydrofolate reductase) is targeted by 17 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting DHFR

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1gentamicin6.30541
2methotrexate6.00404
3trimethoprim5.65283
4pyrimethamine5.36211
5Methotrexate5.02150
6diflunisal4.1764
7mefenamic acid3.9350
8raltitrexed3.5835
9teriflunomide3.5634
10brequinar3.3728
11Pemetrexed3.1422
12dideazafolate2.4010
13pralatrexate2.087
14egcg0.691
15Folic Acid0.691
16Leucovorin0.691
17Sulfadiazine0.691

About DHFR as a Drug Target

DHFR (dihydrofolate reductase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 17 compounds with documented DHFR interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

DHFR inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.